

Frank Porreca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2121882/publications.pdf>

Version: 2024-02-01

105
papers

4,868
citations

109321

35
h-index

110387

64
g-index

106
all docs

106
docs citations

106
times ranked

5194
citing authors

#	ARTICLE	IF	CITATIONS
1	Reward and motivation in pain and pain relief. <i>Nature Neuroscience</i> , 2014, 17, 1304-1312.	14.8	370
2	Spinal and Supraspinal Mechanisms of Neuropathic Pain. <i>Annals of the New York Academy of Sciences</i> , 2000, 909, 12-24.	3.8	220
3	Triptan-induced latent sensitization: A possible basis for medication overuse headache. <i>Annals of Neurology</i> , 2010, 67, 325-337.	5.3	181
4	Nausea and Vomiting Side Effects with Opioid Analgesics during Treatment of Chronic Pain: Mechanisms, Implications, and Management Options. <i>Pain Medicine</i> , 2009, 10, 654-662.	1.9	175
5	Brain Circuits Encoding Reward from Pain Relief. <i>Trends in Neurosciences</i> , 2015, 38, 741-750.	8.6	174
6	The ACTTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multidimensional Approach to Classifying Chronic Pain Conditions. <i>Journal of Pain</i> , 2014, 15, 241-249.	1.4	159
7	Endogenous Opioid Activity in the Anterior Cingulate Cortex Is Required for Relief of Pain. <i>Journal of Neuroscience</i> , 2015, 35, 7264-7271.	3.6	154
8	Pathophysiology, prevention, and treatment of medication overuse headache. <i>Lancet Neurology</i> , The, 2019, 18, 891-902.	10.2	151
9	Post-traumatic headache: epidemiology and pathophysiological insights. <i>Nature Reviews Neurology</i> , 2019, 15, 607-617.	10.1	131
10	Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. <i>Brain</i> , 2015, 138, 28-35.	7.6	120
11	Reward, motivation, and emotion of pain and its relief. <i>Pain</i> , 2017, 158, S43-S49.	4.2	119
12	Amygdala, neuropeptides, and chronic pain-related affective behaviors. <i>Neuropharmacology</i> , 2020, 170, 108052.	4.1	109
13	Development of delta opioid peptides as nonaddicting analgesics. <i>Pharmaceutical Research</i> , 1991, 08, 1-8.	3.5	105
14	Lost but making progress—Where will new analgesic drugs come from?. <i>Science Translational Medicine</i> , 2014, 6, 249sr3.	12.4	102
15	Mechanisms of craniofacial pain. <i>Cephalalgia</i> , 2017, 37, 613-626.	3.9	101
16	Kappa Opioid Receptor Distribution and Function in Primary Afferents. <i>Neuron</i> , 2018, 99, 1274-1288.e6.	8.1	100
17	The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 278-284.	3.4	97
18	Long-lasting antinociceptive effects of green light in acute and chronic pain in rats. <i>Pain</i> , 2017, 158, 347-360.	4.2	81

#	ARTICLE	IF	CITATIONS
19	Central Sensitization and Neuropathic Features of Ongoing Pain in a Rat Model of Advanced Osteoarthritis. <i>Journal of Pain</i> , 2016, 17, 374-382.	1.4	75
20	Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain. <i>Pain</i> , 2019, 160, 824-832.	4.2	75
21	Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. <i>Pain</i> , 2017, 158, 2386-2395.	4.2	74
22	Conformational restriction of Tyr and Phe side chains in opioid peptides: Information about preferred and bioactive side-chain topology. <i>J. Neurochem.</i> , 1996, 38, 1-12.		73
23	Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. <i>Cephalalgia</i> , 2017, 37, 780-794.	3.9	70
24	De Novo Design, Synthesis, and Biological Activities of High-Affinity and Selective Non-Peptide Agonists of the μ -Opioid Receptor. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4767-4776.	6.4	67
25	Positive emotions and brain reward circuits in chronic pain. <i>Journal of Comparative Neurology</i> , 2016, 524, 1646-1652.	1.6	67
26	CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. <i>Cephalalgia</i> , 2019, 39, 1762-1775.	3.9	66
27	Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 92-107.	2.8	64
28	Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer. <i>Molecular Pain</i> , 2018, 14, 174480691875640.	2.1	57
29	(S)-Iacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. <i>Pain</i> , 2016, 157, 1448-1463.	4.2	54
30	Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. <i>Journal of Controlled Release</i> , 2018, 270, 135-144.	9.9	51
31	Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. <i>Cephalalgia</i> , 2020, 40, 892-902.	3.9	47
32	Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain. <i>Pain</i> , 2018, 159, 2512-2521.	4.2	46
33	Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain. <i>Pain</i> , 2019, 160, 1614-1621.	4.2	45
34	Cyclic Enkephalin Analogues with Exceptional Potency and Selectivity for μ -Opioid Receptors. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3957-3962.	6.4	42
35	Substance P and Inflammatory Pain: Getting It Wrong and Right Simultaneously. <i>Neuron</i> , 2019, 101, 353-355.	8.1	42
36	Synthesis and biological activity of the first cyclic biphalin analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 367-372.	2.2	39

#	ARTICLE	IF	CITATIONS
37	Cognition in the Chronic Pain Experience: Preclinical Insights. <i>Trends in Cognitive Sciences</i> , 2021, 25, 365-376.	7.8	38
38	Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain. <i>Pain</i> , 2016, 157, 2731-2738.	4.2	38
39	Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1147-1158.	3.5	37
40	Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1761-1780.	6.4	35
41	Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of the amygdala requires endogenous opioid signaling in the anterior cingulate cortex. <i>Pain</i> , 2020, 161, 609-618.	4.2	34
42	Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8 and 10. <i>International Journal of Peptide and Protein Research</i> , 1993, 42, 411-419.	0.1	32
43	Effects of Modifications of Residues in Position 3 of Dynorphin A(1-11)-NH ₂ on κ Receptor Selectivity and Potency. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2456-2460.	6.4	31
44	Design, Synthesis, and Biological Activities of Cyclic Lactam Peptide Analogues of Dynorphin A(1-11)-NH ₂ . <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1136-1141.	6.4	31
45	Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine. <i>Cephalalgia</i> , 2017, 37, 1350-1372.	3.9	31
46	New potent biphalin analogues containing p-fluoro-l-phenylalanine at the 4,4-positions and non-hydrazine linkers. <i>Amino Acids</i> , 2011, 40, 1503-1511.	2.7	30
47	Novel Cyclic Biphalin Analogue with Improved Antinociceptive Properties. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1032-1036.	2.8	30
48	Exploring the Structure-Activity Relationships of [1-(4-tert-Butyl-3-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), A High-Affinity and Selective μ -Opioid Receptor Nonpeptide Agonist Ligand. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5359-5368.	6.4	29
49	Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial. <i>Cephalalgia</i> , 2021, 41, 135-147.	3.9	29
50	α -Azido acids for direct use in solid-phase peptide synthesis. <i>Journal of Peptide Science</i> , 2000, 6, 594-602.	1.4	28
51	Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist and Neurokinin-1 antagonist peptidomimetics. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 64-77.	5.5	27
52	Decreased dopaminergic inhibition of pyramidal neurons in anterior cingulate cortex maintains chronic neuropathic pain. <i>Cell Reports</i> , 2021, 37, 109933.	6.4	27
53	Impact of chronic migraine attacks and their severity on the endogenous μ -opioid neurotransmission in the limbic system. <i>NeuroImage: Clinical</i> , 2019, 23, 101905.	2.7	26
54	Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. <i>Cephalalgia</i> , 2019, 39, 617-625.	3.9	26

#	ARTICLE	IF	CITATIONS
55	Green Light Exposure Improves Pain and Quality of Life in Fibromyalgia Patients: A Preliminary One-Way Crossover Clinical Trial. <i>Pain Medicine</i> , 2021, 22, 118-130.	1.9	26
56	Peptide Targeting and Delivery across the Blood-Brain Barrier Utilizing Synthetic Triglyceride Esters: Design, Synthesis, and Bioactivity. <i>Bioconjugate Chemistry</i> , 1997, 8, 434-441.	3.6	25
57	Orphanin-FQ/nociceptin: Lack of antinociceptive, hyperalgesic or allodynic effects in acute thermal or mechanical tests following intracerebroventricular or intrathecal administration to mice or rats. <i>European Journal of Pain</i> , 1998, 2, 267-278.	2.8	25
58	Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 2471-2475.	2.2	25
59	An Emerging Role for Prolactin in Female-Selective Pain. <i>Trends in Neurosciences</i> , 2020, 43, 635-648.	8.6	25
60	Kappa opioid receptor activation in the amygdala disinhibits CRF neurons to generate pain-like behaviors. <i>Neuropharmacology</i> , 2021, 185, 108456.	4.1	25
61	Efficacy of (S)-lacosamide in preclinical models of cephalic pain. <i>Pain Reports</i> , 2016, 1, e565.	2.7	24
62	Retrovirus-Mediated Expression of an Artificial β -Endorphin Precursor in Primary Fibroblasts. <i>Journal of Neurochemistry</i> , 2002, 64, 475-481.	3.9	23
63	Selective deficiencies in descending inhibitory modulation in neuropathic rats: implications for enhancing noradrenergic tone. <i>Pain</i> , 2018, 159, 1887-1899.	4.2	23
64	Interaction of β -funaltrexamine with [3H]cycloFOXY binding in rat brain: Further evidence that β -FNA alkylates the opioid receptor complex. <i>Synapse</i> , 1991, 8, 86-99.	1.2	22
65	A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. <i>Cephalalgia</i> , 2021, 41, 305-317.	3.9	21
66	Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. <i>Cephalalgia</i> , 2020, 40, 1535-1550.	3.9	17
67	CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. <i>Cephalalgia</i> , 2021, 41, 749-759.	3.9	17
68	Introducing descending control of nociception: a measure of diffuse noxious inhibitory controls in conscious animals. <i>Pain</i> , 2021, 162, 1957-1959.	4.2	17
69	Discovery of Novel Multifunctional Ligands with $\frac{1}{4}$ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8573-8583.	6.4	16
70	Synthesis and biological properties of β -MePhe ³ analogues of deltorphin I and dermenkephalin: influence of biased X ¹ of Phe ³ residues on peptide recognition for β -opioid receptors. <i>Chemical Biology and Drug Design</i> , 1997, 50, 48-54.	1.1	15
71	Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light. <i>Journal of Pain</i> , 2019, 20, 1293-1306.	1.4	15
72	Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache. <i>Cephalalgia</i> , 2020, 40, 68-78.	3.9	15

#	ARTICLE	IF	CITATIONS
73	Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3716-3720.	2.2	14
74	A prolactin-dependent sexually dimorphic mechanism of migraine chronification. <i>Cephalalgia</i> , 2022, 42, 197-208.	3.9	14
75	Relief of neuropathic pain by cell-specific manipulation of nucleus accumbens dopamine D1- and D2-receptor-expressing neurons. <i>Molecular Brain</i> , 2022, 15, 10.	2.6	14
76	The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia. <i>Neuropharmacology</i> , 2018, 141, 260-271.	4.1	13
77	Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat μ opioid receptor. <i>Synapse</i> , 1998, 28, 117-124.	1.2	12
78	Extracellular N-acetylaspartylglutamate released in the nucleus accumbens modulates the pain sensation: Analysis using a microdialysis/mass spectrometry integrated system. <i>Molecular Pain</i> , 2018, 14, 174480691875493.	2.1	12
79	Sexual dimorphism in functional pain syndromes. <i>Science Translational Medicine</i> , 2021, 13, eabj7180.	12.4	12
80	Structure-activity relationships of non-opioid [des-Arg ⁷]-dynorphin A analogues for bradykinin receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4976-4979.	2.2	11
81	Modification of amphipathic non-opioid dynorphin A analogues for rat brain bradykinin receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 30-33.	2.2	11
82	Structure-Activity Relationships of [des-Arg ⁷]Dynorphin A Analogues at the μ Opioid Receptor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10291-10298.	6.4	11
83	A new hypothesis linking oxytocin to menstrual migraine. <i>Headache</i> , 2021, 61, 1051-1059.	3.9	11
84	Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4683-4688.	2.2	10
85	Activation of dura-sensitive trigeminal neurons and increased c-Fos protein induced by morphine withdrawal in the rostral ventromedial medulla. <i>Cephalalgia</i> , 2017, 37, 407-417.	3.9	10
86	Delta opioid receptor selective ligands; DPLPE-deltorphin chimeric peptide analogues. <i>International Journal of Peptide and Protein Research</i> , 1994, 44, 80-84.	0.1	8
87	Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance. <i>Brain</i> , 2023, 146, 1186-1199.	7.6	8
88	Discovery of Stable Non-opioid Dynorphin A Analogues Interacting at the Bradykinin Receptors for the Treatment of Neuropathic Pain. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1746-1752.	3.5	7
89	Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3664-3667.	3.0	6
90	Inhibition of experimental visceral pain in rodents by cebranopadol. <i>Behavioural Pharmacology</i> , 2019, 30, 320-326.	1.7	6

